Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-CTLA-4/CD152 Antibody
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T9901A-1254 Copy Product Info
Purity: 95%
🥰Excellent
Anti-CTLA-4/CD152 Antibody is a humanized monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4/CD152). This product specifically binds to the extracellular domain of CTLA-4, blocking its interaction with ligands CD80 (B7-1) and CD86 (B7-2). This blockade removes the negative regulatory signal of CTLA-4 on T-cell activation, thereby enhancing T-cell proliferation, cytokine production, and anti-tumor immune responses.
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | Inquiry | Inquiry | |
| 5 mg | $695 | Inquiry | Inquiry | |
| 10 mg | $1,090 | Inquiry | Inquiry | |
| 25 mg | $1,980 | Inquiry | Inquiry | |
| 50 mg | $3,280 | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Antibody Information
Storage & Solubility Information
| Description | Anti-CTLA-4/CD152 Antibody is a humanized monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4/CD152). This product specifically binds to the extracellular domain of CTLA-4, blocking its interaction with ligands CD80 (B7-1) and CD86 (B7-2). This blockade removes the negative regulatory signal of CTLA-4 on T-cell activation, thereby enhancing T-cell proliferation, cytokine production, and anti-tumor immune responses. |
| In vitro | Anti-CTLA-4/CD152 Antibody binds the CTLA-4 extracellular domain with high affinity. In T-cell assays, it reverses CD80/CD86-induced CTLA-4 inhibition, increasing IL-2 and IFN-γ production and restoring effector T-cell proliferation [1]. |
| In vivo | In preclinical tumor models, systemic administration of Anti-CTLA-4/CD152 Antibody leads to a reduction in tumor growth and a significant increase in the ratio of effector T cells to regulatory T cells (Tregs) within the tumor microenvironment; the treatment enhances the overall anti-tumor immune response by modulating the inhibitory checkpoints that normally limit T-cell activity during tumor progression [1]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | CTLA-4/CD152 |
| Isotype | IgG1 |
| Storage | Store at low temperature Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: Anti-CTLA-4/CD152 Antibody chemical structure | Anti-CTLA-4/CD152 Antibody in vivo | Anti-CTLA-4/CD152 Antibody in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.